Qualigen Therapeutics, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
CTLTCatalent, Inc. -0.84%84.162.1%$220.94m
JAZZJazz Pharmaceuticals Plc -3.27%137.262.4%$157.42m
SAVACassava Sciences, Inc. -7.55%9.310.0%$150.48m
HZNPHorizon Therapeutics Plc -2.01%78.325.8%$149.40m
CORTCorcept Therapeutics, Inc. -3.06%17.445.5%$122.14m
VRXValeant Pharmaceuticals International, Inc. -4.39%16.4414.1%$96.74m
BHCBausch Health Cos., Inc. -4.41%16.430.0%$68.08m
AMRNAmarin Corp. Plc -3.12%4.041.5%$54.96m
MYOKMyoKardia, Inc. -9.20%124.001.8%$52.39m
ARGXargenx SE -2.63%243.180.0%$52.12m
SAGESAGE Therapeutics, Inc. -3.72%60.138.6%$44.72m
GWPHGW Pharmaceuticals Plc -0.80%99.386.2%$40.41m
AXSMAxsome Therapeutics, Inc. -3.70%78.631.9%$37.57m
MRNSMarinus Pharmaceuticals, Inc. -3.61%3.341.9%$37.30m
PRGOPerrigo Co. Plc -3.72%45.326.8%$34.57m

Company Profile

Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARSâ„¢. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company is headquartered in Los Angeles, CA.